2 March 2022

ASX Announcement

AdAlta granted Chinese patent protecting AD-214

MELBOURNE Australia, 3 February 2022: AdAlta Limited (ASX:1AD), the clinical stage biotechnology company developing novel therapeutic products from its i-body platform, is pleased to announce that its first Chinese patent relating to lead program, AD-214, has been granted by the China National Intellectual Property Administration.

Patent Number CN 107427574 B, entitled "CXCR4 binding molecules", has an expiry date of 8 January 2036.

The new patent protects the i-body sequence used in AdAlta's lead product, AD-214, sequences similar to this, and pharmaceutical compositions and derivatives containing these i-body sequences. The patent also protects the use of these sequences in therapeutic and diagnostic applications, including Idiopathic Pulmonary Fibrosis (IPF), the lead indication for which AD-214 is being developed.

Patents are granted on a country-by-country basis, and China is the fifth country to grant patent protection under this application, following Australia (two patents), US (two patents), Japan and Singapore. Claims are being pursued in other major markets including the European Union and India.

AdAlta's CEO and Managing Director, Dr Tim Oldham said:

"China is now the second largest (and fastest growing) pharmaceutical market in the world (after the US),[1,2] representing 11%[3] of the global prescription drug market. IPF is included in the Chinese Rare Diseases List, including it as part of China's plan to increase availability of drugs for rare diseases.[4] Patent protection for AD-214 in this important market is anticipated to further increase the already significant interest from potential China partners."

Authorised for lodgement by:

Tim Oldham
CEO and Managing Director
February 2022

[1] https://www.pharmexec.com/view/drug-developments-in-china-a-global-opportunity
[2] https://www.statista.com/statistics/245473/market-share-of-the-leading-10-global-pharmaceutical-markets/
[3] https://daxueconsulting.com/pharmaceutical-industry-china
[4] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5982625/

AdAlta Limited
15/2 Park Drive
Bundoora VIC 3083 Australia
T +61 3 9479 5159
E enquiries@adalta.com.au
ABN 92 120 332 925
adalta.com.au

Notes to editor

About AdAlta

AdAlta Limited is a clinical stage drug development company headquartered in Melbourne, Australia. The Company is using its proprietary i-body technology platform to solve challenging drug targeting problems and generate a promising new class of single domain antibody protein therapeutics with the potential to treat some of today's most challenging medical conditions.

The i-body technology mimics the shape and stability of a unique and versatile antigen binding domain that was discovered initially in sharks and then developed as a human protein. The result is a range of unique proteins capable of interacting with high selectivity, specificity and affinity with previously difficult to access targets such as G-protein coupled receptors (GPCRs) that are implicated in many serious diseases. i-bodies are the first fully human single domain antibody scaffold and the first based on the shark motif to reach clinical trials.

AdAlta has completed Phase I clinical studies for its lead i-body candidate, AD-214, that is being developed for the treatment of Idiopathic Pulmonary Fibrosis (IPF) and other human fibrotic diseases for which current therapies are sub-optimal and there is a high unmet medical need.

The Company is also entering collaborative partnerships to advance the development of its i-body platform. It has an agreement with GE Healthcare to co-develop i-bodies as diagnostic imaging agents against Granzyme B, a biomarker of response to immunooncology drugs, a program now in preclinical development. It also has a collaboration with Carina Biotech to co-develop precision engineered, i-body enabled CAR-T cell therapies to bring new hope to patients with cancer.

AdAlta's strategy is to maximise the products developed using its next generation i-body platform by internally discovering and developing selected i-body enabled product candidates against GPCRs implicated in fibrosis, inflammation and cancer and partnering with other biopharmaceutical companies to develop product candidates against other classes of receptor, in other indications, and in other product formats.

Further information can be found at: https://adalta.com.au

For more information, please contact:

Investors

Tim Oldham, CEO & Managing Director
Tel: +61 403 446 665
E: t.oldham@adalta.com.au

Media

IR Department
Tel: +61 411 117 774
E: jane.lowe@irdepartment.com.au